Carcinoembryonic Antigen (CEA) Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 – 2032
The Global Carcinoembryonic Antigen (CEA) Market was valued at USD 2.2 billion in 2023 and is projected to grow at a 6.3% CAGR from 2024 to 2032. The market expansion is largely driven by the rising incidence of cancers such as colorectal, lung, and breast cancers worldwide. According to the World Health Organization (WHO), the global cancer burden is expected to surge, with around 27 million new cases and 16 million cancer-related deaths anticipated by 2040. Colorectal cancer is the third most common type globally, accounting for 10% of all cancer diagnoses and ranking second in cancer-related mortality. The increasing cancer prevalence has fueled the demand for CEA tests, which are essential for monitoring treatment responses, detecting recurrences, and aiding in early diagnosis. By application, the CEA market is segmented into gastrointestinal, breast, lung, ovarian, prostate, and thyroid cancers.
The gastrointestinal cancer segment dominated the market in 2023, holding a 41.4% share and is expected to grow at a 6.7% CAGR over the forecast period. This segment encompasses various cancers, including colorectal, pancreatic, liver, stomach, esophageal, gall bladder, and anal cancers, with CEA tests playing a crucial role in monitoring these conditions. The market is also categorized by gender, with the male segment capturing a substantial share of 54.8% in 2023. This segment is projected to reach a market size of USD 2.1 billion by 2032. The high prevalence of cancers such as colorectal, lung, and prostate cancers in men has led to increased adoption of CEA testing. While CEA is not the primary biomarker for prostate cancer, it is frequently used alongside other diagnostics to track disease progression and treatment outcomes, making it a valuable tool in men's cancer care.In terms of regional analysis, the U.S. led the North American CEA market, generating USD 830.1 million in revenue in 2023, with significant growth expected over the coming years. The U.S. market's dominance can be attributed to its advanced healthcare infrastructure, high prevalence of gastrointestinal cancers, and ongoing research efforts. Additionally, the country's leadership in diagnostic innovation has enhanced the accuracy and reliability of CEA assays, further driving the market's growth in the region.
The gastrointestinal cancer segment dominated the market in 2023, holding a 41.4% share and is expected to grow at a 6.7% CAGR over the forecast period. This segment encompasses various cancers, including colorectal, pancreatic, liver, stomach, esophageal, gall bladder, and anal cancers, with CEA tests playing a crucial role in monitoring these conditions. The market is also categorized by gender, with the male segment capturing a substantial share of 54.8% in 2023. This segment is projected to reach a market size of USD 2.1 billion by 2032. The high prevalence of cancers such as colorectal, lung, and prostate cancers in men has led to increased adoption of CEA testing. While CEA is not the primary biomarker for prostate cancer, it is frequently used alongside other diagnostics to track disease progression and treatment outcomes, making it a valuable tool in men's cancer care.In terms of regional analysis, the U.S. led the North American CEA market, generating USD 830.1 million in revenue in 2023, with significant growth expected over the coming years. The U.S. market's dominance can be attributed to its advanced healthcare infrastructure, high prevalence of gastrointestinal cancers, and ongoing research efforts. Additionally, the country's leadership in diagnostic innovation has enhanced the accuracy and reliability of CEA assays, further driving the market's growth in the region.
Report Content
CHAPTER 1 METHODOLOGY & SCOPE
1.1 Market segmentation
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates and calculations
1.3.1 Base year calculations
1.3.2 Key trends for market estimates
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Industry 360° synopsis
CHAPTER 3 INDUSTRY INSIGHTS
3.1 Industry ecosystem
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising in cancer prevalence
3.2.1.2 Growing demand for minimally invasive diagnostic procedures
3.2.1.3 Recent technological advancements in carcinoembryonic antigen diagnostics
3.2.1.4 Increasing per capita healthcare expenditure
3.2.2 Industry pitfalls & challenges
3.2.2.1 Inability to detect early-stage cancer
3.2.2.2 Lack of awareness regarding the application of carcinoembryonic antigen tests
3.3 Growth potential analysis
3.4 Regulatory landscape
3.4.1 U.S.
3.4.2 Europe
3.5 Global incidence of top cancers, by region, 2023
3.5.1 North America cancer incidence
3.5.2 Europe cancer incidence
3.5.3 Asia Pacific cancer incidence
3.5.4 Latin America cancer incidence
3.5.5 Middle East & Africa cancer incidence
3.6 Clinical studies landscape
3.7 Porter's analysis
3.8 PESTEL analysis
CHAPTER 4 COMPETITIVE LANDSCAPE, 2023
4.1 Introduction
4.1.1 F. Hoffmann-La Roche Ltd.
4.1.2 Quest Diagnostics Incorporated
4.1.3 Thermo Fisher Scientific Inc.
4.2 Competitive analysis of major market players
4.3 Company matrix analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
CHAPTER 5 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2021 – 2032 ($ MN)
5.1 Key trends
5.2 Gastrointestinal cancer
5.2.1 Colorectal cancer
5.2.2 Pancreatic cancer
5.2.3 Liver cancer
5.2.4 Stomach cancer
5.2.5 Esophageal cancer
5.2.6 Gall bladder cancer
5.2.7 Anal cancer
5.3 Breast cancer
5.4 Lung cancer
5.5 Ovarian cancer
5.6 Prostate cancer
5.7 Thyroid cancer
CHAPTER 6 MARKET ESTIMATES AND FORECAST, BY GENDER, 2021 – 2032 ($ MN)
6.1 Key trends
6.2 Male
6.3 Female
CHAPTER 7 MARKET ESTIMATES AND FORECAST, BY END-USER, 2021 – 2032 ($ MN)
7.1 Key trends
7.2 Hospitals
7.3 Diagnostic laboratories
7.4 Oncology clinics
7.5 Research centers and academic institutes
CHAPTER 8 MARKET ESTIMATES AND FORECAST, BY REGION, 2021 – 2032 ($ MN)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Poland
8.3.7 Russia
8.3.8 Sweden
8.3.9 Switzerland
8.3.10 Netherlands
8.3.11 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 New Zealand
8.4.7 Malaysia
8.4.8 Singapore
8.4.9 Indonesia
8.4.10 Philippines
8.4.11 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.5.4 Columbia
8.5.5 Peru
8.5.6 Rest of Latin America
8.6 Middle East and Africa
8.6.1 Saudi Arabia
8.6.2 South Africa
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
CHAPTER 9 COMPANY PROFILES
9.1 Abcam Limited
9.2 AdvaCare Pharma
9.3 Aviva Systems Biology Corporation
9.4 Boster Biological Technology
9.5 Creative Diagnostics
9.6 Diazyme Laboratories Inc.
9.7 F. Hoffmann-La Roche Ltd.
9.8 Medix Biochemica
9.9 Omega Diagnostics Ltd.
9.10 RayBiotech, Inc.
9.11 Thermo Fisher Scientific Inc.
9.12 Quest Diagnostics Incorporated
CHAPTER 1 METHODOLOGY & SCOPE
1.1 Market segmentation
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates and calculations
1.3.1 Base year calculations
1.3.2 Key trends for market estimates
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Industry 360° synopsis
CHAPTER 3 INDUSTRY INSIGHTS
3.1 Industry ecosystem
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising in cancer prevalence
3.2.1.2 Growing demand for minimally invasive diagnostic procedures
3.2.1.3 Recent technological advancements in carcinoembryonic antigen diagnostics
3.2.1.4 Increasing per capita healthcare expenditure
3.2.2 Industry pitfalls & challenges
3.2.2.1 Inability to detect early-stage cancer
3.2.2.2 Lack of awareness regarding the application of carcinoembryonic antigen tests
3.3 Growth potential analysis
3.4 Regulatory landscape
3.4.1 U.S.
3.4.2 Europe
3.5 Global incidence of top cancers, by region, 2023
3.5.1 North America cancer incidence
3.5.2 Europe cancer incidence
3.5.3 Asia Pacific cancer incidence
3.5.4 Latin America cancer incidence
3.5.5 Middle East & Africa cancer incidence
3.6 Clinical studies landscape
3.7 Porter's analysis
3.8 PESTEL analysis
CHAPTER 4 COMPETITIVE LANDSCAPE, 2023
4.1 Introduction
4.1.1 F. Hoffmann-La Roche Ltd.
4.1.2 Quest Diagnostics Incorporated
4.1.3 Thermo Fisher Scientific Inc.
4.2 Competitive analysis of major market players
4.3 Company matrix analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
CHAPTER 5 MARKET ESTIMATES AND FORECAST, BY APPLICATION, 2021 – 2032 ($ MN)
5.1 Key trends
5.2 Gastrointestinal cancer
5.2.1 Colorectal cancer
5.2.2 Pancreatic cancer
5.2.3 Liver cancer
5.2.4 Stomach cancer
5.2.5 Esophageal cancer
5.2.6 Gall bladder cancer
5.2.7 Anal cancer
5.3 Breast cancer
5.4 Lung cancer
5.5 Ovarian cancer
5.6 Prostate cancer
5.7 Thyroid cancer
CHAPTER 6 MARKET ESTIMATES AND FORECAST, BY GENDER, 2021 – 2032 ($ MN)
6.1 Key trends
6.2 Male
6.3 Female
CHAPTER 7 MARKET ESTIMATES AND FORECAST, BY END-USER, 2021 – 2032 ($ MN)
7.1 Key trends
7.2 Hospitals
7.3 Diagnostic laboratories
7.4 Oncology clinics
7.5 Research centers and academic institutes
CHAPTER 8 MARKET ESTIMATES AND FORECAST, BY REGION, 2021 – 2032 ($ MN)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Poland
8.3.7 Russia
8.3.8 Sweden
8.3.9 Switzerland
8.3.10 Netherlands
8.3.11 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 New Zealand
8.4.7 Malaysia
8.4.8 Singapore
8.4.9 Indonesia
8.4.10 Philippines
8.4.11 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.5.4 Columbia
8.5.5 Peru
8.5.6 Rest of Latin America
8.6 Middle East and Africa
8.6.1 Saudi Arabia
8.6.2 South Africa
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
CHAPTER 9 COMPANY PROFILES
9.1 Abcam Limited
9.2 AdvaCare Pharma
9.3 Aviva Systems Biology Corporation
9.4 Boster Biological Technology
9.5 Creative Diagnostics
9.6 Diazyme Laboratories Inc.
9.7 F. Hoffmann-La Roche Ltd.
9.8 Medix Biochemica
9.9 Omega Diagnostics Ltd.
9.10 RayBiotech, Inc.
9.11 Thermo Fisher Scientific Inc.
9.12 Quest Diagnostics Incorporated
